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Running title: Fox-2 enhances exon 16 splicing in protein 4.1R pre-mRNA 
Activation of protein 4.1R exon 16 (E16) 
inclusion during erythropoiesis represents a 
physiologically important splicing switch that 
increases 4.1R affinity for spectrin and actin. 
Previous studies showed that negative 
regulation of E16 splicing is mediated by the 
binding of hnRNP A/B proteins to silencer 
elements in the exon and that downregulation 
of hnRNP A/B proteins in erythroblasts leads to 
activation of E16 inclusion. This paper 
demonstrates that positive regulation of E16 
splicing can be mediated by Fox-2 or Fox-1, two 
closely related splicing factors that possess 
identical RNA recognition motifs. SELEX 
experiments with human Fox-1 revealed highly 
selective binding to the hexamer UGCAUG. Both 
Fox-1 and Fox-2 were able to bind the 
conserved UGCAUG elements in the proximal 
intron downstream of E16, and both could 
activate E16 splicing in HeLa cell co- 
transfection assays in a UGCAUG-dependent 
manner. Conversely, knockdown of Fox-2 
expression, achieved with two different siRNA 
sequences resulted in decreased E16 splicing. 
Moreover, immunoblot experiments 
demonstrate mouse erythroblasts express Fox- 
2. These findings suggest that Fox-2 is a 
physiological activator of E16 splicing in 
differentiating erythroid cells in vivo. Recent 
experiments show that UGCAUG is present in 
the proximal intron sequence of many tissue- 
specific alternative exons, and we propose that 
the Fox family of splicing enhancers plays an 
important role in alternative splicing switches 
during differentiation in metazoan organisms. 
Alternative splicing of pre-mRNA leads to the 
synthesis of multiple protein isoforms from a 
single gene. It is an important mechanism for 
regulating gene expression and may be utilized by 
40-60% of human genes (1-4). Thus, the estimated 
25,000 to 30,000 genes of the human genome can 
generate a much larger number of proteins. 
Regulation of alternative splicing occurs in both a 
tissue- and developmental-specific manner, 
resulting in alterations in the structure and 
function of critical proteins. Altered splicing 
regulation can also be of widespread importance in 
the etiology of human disease (5-7). 
The protein 4.1 gene family serves as an 
excellent model for investigating the regulation of 
alternative splicing. The four genes that comprise 
the family (4.1R, 4.1G, 4.1B, and 4.1N) display a 
remarkable array of highly regulated, tissue- 
specific splicing events. These alternative splicing 
events facilitate expression of distinct isoforms of 
4.1 protein in cells of erythroid, epithelial, neural, 
and muscle origin (8-14); thus, they provide 
opportunities for understanding the mechanisms 
that regulate alternative splicing in several 
different cell types. To date, mechanistic studies 
have focused predominantly on erythroid cells, in 
which 4.1R protein is a structural component of 
the erythrocyte plasma membrane and is important 
for structural integrity and stability of the 
membrane skeleton. In differentiating erythroid 
progenitor cells, a dramatic switch in pre-mRNA 
splicing results in a physiologically important 
functional change in the encoded structural protein 
isoforms (15,16). 4.1R protein in early 
progenitors, derived from transcripts in which E16 
is skipped, exhbits a low affinity for spectrin and 
actin; in contrast, E16 inclusion in late stage 
erythroblasts generates a high affinity isoform (17- 
20). 
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E16 splicing is influenced by multiple 
regulatory elements located not only in the exon, 
but also in the flanking introns, and at the splice 
sites themselves (21-23). One component of the 
regulatory machinery in erythroid cells is a stage- 
specific repression of E 16 inclusion, mediated by 
binding of hnRNP A/B proteins to exonic splicing 
silencer (ESS) element(s) located within the exon. 
Repression occurs in early erythroid progenitors, 
which express h g h  levels of hnRNP A/B proteins, 
and repression is subsequently relieved by a 
substantial down-regulation of hnRNP A B  
expression in later stage erythroblasts (23). 
Reduction in the level of splicing inhibitory 
proteins thus appears to be a critical feature of the 
physiological E16 splicing switch in erythroid 
cells. 
In this paper, we describe a second mechanism 
whereby E16 splicing efficiency can be regulated, 
in t h s  case via the interaction of splicing activator 
protein(s) with positive regulatory elements in the 
downstream intron. Our results demonstrate 
phylogenetic conservation of UGCAUG splicing 
enhancer motifs downstream of E16, specific 
binding of these elements to both Fox-1 and Fox-2 
splicing factor proteins, and UGCAUGAependent 
stimulation of E16 splicing by both of these 
proteins in functional splicing assays. These 
findings support the emerging model of Fox 
protein splicing factors as important components 
of the cellular machinery that switches on splicing 
of critical alternative exons at appropriate times 
during development and differentiation by acting 
at highly specific UGCAUG intron enhancers (24- 
27). 
MATERIAL AND METHODS 
Nomenclature. The splicing factors described in 
this paper have been reported independently by 
multiple laboratories in different contexts and with 
different names. Fox-1 is also known as ataxin 2 
binding protein (A2BP1; (28)) or 
hexaribonucleotide binding protein 1 (HRNBP 1; 
(29)); Fox-2 has been designated as 
hexaribonucleotide binding protein 2 (HRNBP2; 
(29)), RBM9 (30), or Fxh (31). Both Fox genes 
encode multiple isoforms via alternative splicing; 
e.g., see cDNAs AF094849, AF109106, and 
AF229057 and recent publications (27,32,33). 
Genetic database analysis. Human protein 4.1R 
exon 16 (May 2004 build, chromosome 1 
nucleotides 29207550-292076 12) was used as a 
query sequence with which to retrieve orthologous 
exons from other genomes, as well as flanking 
intron sequences, using the BLAT search tools 
available at www.genome.ucsc.edu/cgi-bidhgBlat. 
4. lG exon 16 is on human chromosome 6 (nt 
131242977-131243039); 4.1B exon 16 is on 
human chromosome 18 (nt 5397436-5397501). 
Plasmids. The wild type 4.1R minigene was 
described earlier (21). In construct 4. lAhex, partial 
deletion of intron 16 sequences yielded a pre- 
mRNA that retained 21 nt of proximal intron 16 
sequences joined at an Xbd site to the terminal 
249 nt of intron 16 and exon 17; all three UGCAUG 
elements were removed. Derivatives of 4.1 Ahex 
were constructed by inserting synthetic 
oligonucleotides containing two copies of either a 
wild type (5'-GATCATGCATGAGGGAAAGGTGCAT 
GCAAAGGGAA-3') or a mutated UGCAUG hexamer 
( ~'-GATCATGACTGAGGGAAAGGTGACTGCAAA- 
GGGAA-3'). 
Mammalian expression clones for mFox-2a 
(BC002124) and mFox-2P (BC027263) were 
obtained from Research Genetics. The human 
Fox-la cDNA (AF094849) was cloned in one of 
our laboratories (JCW) and inserted into the 
expression vector pcDNA3.1 -Myc-His(-) between 
the XbaI and Hind111 sites. 
siRNAs. Duplex siRNAs obtained from 
Dharmacon were as follows: Fox-2 siRNA duplex 
1 : sense strand, 5'-GACAGUAUAUGGUG- 
CAGUCUU; antisense strand, 5'-PGACUGCA- 
CCAUAUACUGUCUU. Fox-2 siRNA duplex 2: 
sense strand, 5'-CGAGAAUAGUGCUGAUG- 
CAUU; antisense strand, 5'-PUGCAUCAG- 
CACUAUUCUCGUU. 
Splicing analysis. HeLa cells were transfected 
with plasmid DNAs using Lipofectamine 2000 
according to the manufacturer's instructions 
(Invitrogen). Transfections with siRNA were 
performed for 24 hrs in 6 well culture dishes using 
200 pmol of siRNA. Total RNA was isolated 72 
hrs later using RNeasy columns (Qiagen). First 
strand cDNA was synthesized from the isolated 
RNA with Superscript I1 reverse transcriptase 
(Invitrogen) and an exon 17 3' primer. PCR 
analysis of spliced 4.1 pre-mRNA was performed 
using DNA primers located in exon 13 (forward 
primer: 5 '-AGCCATTGCTCAGAGTCAGG-3 ') 
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and exon 17 (reverse primer: 5’- 
GCGAATTCCCGGATTCAGT-3’) of the 4.1 
minigene. 
Immunoblot analysis. HeLa cell protein extracts 
for immunoblot analysis were prepared by lysis in 
Novex Tris-Glycine-SDS-buffer (Invitrogen) + 
DTT and boiled for 10 min. Anti-Fox-2 antiserum 
(Washington Biotechnology) was raised in rabbits 
against a synthetic peptide, GVPHTQDYAGQT. 
This peptide was selected on the basis of its 
conservation between mouse and human Fox-2 
and its divergence from mouse and human Fox-1. 
The Fox-2 antibody used in these experiments was 
affinity purified against a synthetic peptide 
(GenScript Corporation) by using Affi-Gel@ 10 
(BioRad) according to the manufacturer’s 
instructions, and was diluted 1:lOO in milk 
blotto/PBS-T solution. For the detection of actin 
the antibody (Cytoskeleton) was used at 1:5000 
dilution. The secondary antibody was goat-anti- 
rabbit IgG conjugated to HRP (1:5000 dilution). 
For signal detection, the Western Lightning 
Chemiluminescence Reagent Kit was employed 
(Perkin Elmer Life Sciences). 
Mouse erythroblasts were obtained from the 
spleens of mice infected with the Friend virus, 
anemia-inducing strain (FVA), and cultured as 
previously described (34,35). Cells differentiate 
from proerythroblasts to enucleated reticulocytes 
over -44-48 hrs in culture. Protein was extracted 
from the cultured cells and analyzed by 
immunoblot analysis. 
SELEX analysis of Fox-1 binding specijcity. For 
systematic evolution of ligands by exponential 
enrichment (SELEX) (36), 500 pg of hFox-la- 
myc-his protein, isolated from a baculovirus/SF9- 
expression system, was coupled to 1 ml NHS- 
activated Sepharose 4B beads (Pharmacia). The 
oligonucleotides used for SELEX were identical or 
similar to those used previously (37,38): 
SELN40: 5’- 
GGCACTATTTATATCAACTAGAACTACTGG 
ATCCG(N),oTTGGTA- 
CCCAATTCGCCCTATAGTGAGTCGTATTA- 
3’ (N40 representing 40 nucleotides of random 
sequence) 
SELF: 5’- 
TAATACGACTCACTATAGGGCGAATTGGG 
TACCAA-3’ (for PCR) 
SELREVl 5’-GGCACTATTTATATCAAC-3’ 
(for reverse transcription) 
SELREV2: 5’- 
GGCACTATTTATATCAACTAGAACTACTGG 
ATCCG-3’ (for PCR). The SELEX was performed 
as previously described with some modification 
(39). 100 pg of SELF and 300 pg of SELN40 were 
annealed as the template for in vitro transcription 
using &boprobe@ in vitro Transcription System 
(Promega). The synthesized RNA was extracted 
with phenol/chloroform, precipitated, and 
dissolved in Binding Buffer (0.1 M NaC1, 50 mM 
Tris-HC1, pH 8.0, 14.4 mM P-mercaptoethanol) 
containing 4mg/ml tRNA. Approximately 1 mg of 
RNA was loaded onto the 1 ml hFox1a-Sepharose 
4B column equilibrated with Binding Buffer, 
mixed and mildly rotated at room temperature for 
10 min. The column was washed with 10 ml of 
Binding Buffer and eluted with 10 ml of 0.1 M 
NaC1, MTPBS (16 mM Na2HP04, 4 mM 
NaH2P04, pH 7.3) followed by 10 ml of 1.0 M 
NaC1, MTPBS. The first 10 fractions (0.5 ml 
each) eluted by 1 M NaC1, MTPBS were collected, 
and the RNA was precipitated and dissolved in 
DEPC-treated H20. One fifth of the RNA was 
reverse transcribed and amplified (22 cycles of 94 
“C 45 sec, 65 “C 45 sec and 72 “C 45 sec). The 
amplified PCR product was resolved by 2% 
agarose gel electrophoresis. Fractions 2, 3 and 4 
eluted with 1 M NaC1, MTPBS were pooled as 
templates for the next round of SELEX. Beginning 
with the fourth round, the concentration of NaCl 
was increased to 0.4 M in both the Binding Buffer 
and the first elution buffer. A total of seven rounds 
of SELEX were performed. The PCR product of 
the final round was digested with KpnI and 
BamHI and cloned to pBluescript vector. 
Individual clones were selected and sequenced. 
In vitro synthesis of hFox-1 and mFox-2 proteins. 
Human Fox-la cDNA from clone AF094849 was 
amplified using primers hBP1-S (5’- 
CACCAGCATGCTGGCGTCTCAAGGAGTTCT 
c-3’) and hBP 1 -AS (5’- 
and cloned into the bacterial expression vector 
pEXP 1-DEST (Invitrogen). The resulting hFox-1 
construct, tagged at the N-terminus with the 
Express epitope and a six-histidine epitope, was 
synthesized by in vitro transcriptiodtranslation 
using Expressway Plus (Invitrogen) according to 
the manufacturer’s instructions. Mouse Fox-2P 
cDNA was amplified from clone BC027263 using 
TTAGTATGGAGCAAAACGGTTGTATCC-3’) 
primers mBP2-S (5’- 
3 
CACCCGGATGGCGGAAGGCGGCCAGGCGC 
A-3' and mBP2-AS (5'- 
CTAGTAGGGGGCAAATCGGCTGTAGCC-3'). 
and cloned into pEXP1-DEST for in vitro 
expression. 
Binding of recombinant Fox proteins to 
biotinylated RNAs containing UGCAUG. 40-mer 
RNAs representing nt 79-118 of intron 16 
sequence were purchased from Dharmacon. Wild 
type RNA sequence: 5' biotin- 
GCCCUUGGGUUUGCAUGCCACUGCAUGA 
GAGACGUUUmAmG-3'; mutant sequence: 5' 
biotin- 
GCCCUUGGGUUUGacUGCCACUGacUGAGA 
GACGUUUmAmG; (hexamer motifs are 
underlined and mutations represented in lower 
case). Binding experiments were performed 
essentially as previously described (23). Briefly, 
recombinant hFox-1 or mFox-2 or hnRNP A1 was 
incubated with 100 pmol of biotinylated-RNA in 
splicing buffer for 30 min at 4 "C; RNA and 
associated proteins were then removed by binding 
to streptavidin-conjugated magnetic beads (Dynal) 
according to the manufacturer's instructions. 
RESULTS 
Binding specijcity of mammalian Fox splicing 
factor proteins for the hexamer UGCAUG. The 
consensus binding site of the zebrafish splicing 
factor, zFox-1, was defined as the pentamer 
GCAUG (24). We independently cloned human 
Fox-1 (hFox-1) cDNA and examined its binding 
specificity via SELEX. As shown in Figure 1, all 
of the winner sequences binding to hFox-1 
contained at least one copy of the same pentamer 
recognized by zFox-1, and four contained two 
copies (sequence #6, 10, 26, 45). However, closer 
examination revealed that the great majority 
(45/47) of winner sequences for the human protein 
contained the hexamer UGCAUG, with an 
additional preference for u in the seventh position, 
i.e., UGCAUGU. These results are consistent with 
the recent structural analysis of a FOX-~-UGCAUGU 
complex (40). This extended consensus binding 
site for hFox-1 may reflect evolutionary changes 
in the protein from fish to mammals. 
Alternatively, the minor difference in binding 
specificity may be due to the fact that the reported 
zebrafish Fox-1 is not the best ortholog of human 
Fox-1; i.e., a closer homolog with higher identity 
to the human Fox-1 RRM is encoded in the 
zebrafish genome (our unpublished observations). 
The powerful selection for winners with multiple 
UGCAUG elements may reflect cooperative binding 
of hFox-1 to regions with multiple binding sites. 
Notably, several of the natural occurrences of 
intronic UGCAUG or GCAUG splicing elements, 
including the 4.1 gene reported here, contain 
multiple elements (22,32,4 1-44). 
Figure 2 shows the domain structure of 
mammalian Fox-1 and two closely related Fox-2/ 
RBM9/HRNBP2 protein isoforms (hereafter called 
Fox-2) that are used for functional studies in this 
paper. The Fox-2 proteins possess different C- 
terminal domains and are derived from the same 
gene via alternative splicing, while Fox-1 is 
encoded by a separate gene. A C-terminal isoform 
of Fox-1 is also encoded by alternative splicing, 
but was not studied here. All of these mammalian 
Fox proteins are 100% identical in the RRM 
domain. Outside of the RRM domain, the proteins 
exhibit a reduced but still hghly significant 
homology, except for the aforementioned 
alternative C-terminus. The functional splicing 
experiments described below demonstrate that 
these novel Fox proteins can promote exon 
inclusion in a UGCAUG-dependent manner. 
UGCAUG elements &nction as intron splicing 
enhancers for protein 4.1R exon 16. E16 in the 
4.1R gene undergoes a splicing switch during 
erythropoiesis, being skipped in early progenitor 
cells and efficiently included at later stages 
(Figure 3, top). Three repeats of the UGCAUG 
hexamer are located downstream of protein 4.1R 
E16 in the human and mouse genes, and mutations 
of these elements have been reported to decrease 
E16 inclusion (22). As shown in Figure 3, bottom 
panel, the presence of UGCAUG elements has been 
highly conserved in evolution, as 2-3 repeats are 
also located in the E16 proximal intronic regions 
of the rat, opossum, chicken, frog, and tetraodon 
(fish) 4.1R genes. In addition, two closely 
paralogous genes (4.lG and 4.1B) also possess 
UGCAUG repeats near alternative E16, although the 
surrounding intron sequences are otherwise quite 
divergent. These observations support a functional 
role for UGCAUG in regulating E 16 splicing. 
In order to test whether the conserved UGCAUG 
elements could function as enhancers or silencers 
of E16 splicing, several 4.1 pre-mRNA constructs 
possessing or lacking intronic hexamers were 
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compared in functional splicing assays in 
transfected HeLa cells. As shown in figure 4, the 
wild type transcript with three hexamers yielded a 
modest inclusion efficiency for E16 (43%) among 
its spliced products (lane 1). In contrast, deletion 
of an intronic region containing all three hexamers 
resulted in complete loss of E16 inclusion 
(construct 4.lAhex; lane 2). T h s  result was 
consistent with a model in whch deletion of an 
intronic enhancer was responsible for reduced E16 
splicing efficiency. Additional constructs were 
therefore designed to test whether the UGCAUG 
hexamers represented the active enhancer 
element(s). Splicing of construct 4. lAhexW, 
containing UGCAUG elements reinserted at the site 
of the deletion, rescued splicing efficiency to near 
wild type levels (Figure 4, lane 3). Negative 
control construct 4. lAhexmut, containing a two 
nucleotide mutation in the inserted hexamer 
elements, did not rescue E16 splicing (Figure 4, 
lane 4). Additional construct pairs containing wild 
type or mutant hexamers with different flanking 
nucleotides were also tested. Whle the wild type 
hexamers consistently yielded much higher exon 
inclusion efficiency than the comparable mutant 
hexamers, it was also clear that neighboring 
sequences could influence the magnitude of these 
effects (results not shown). 
Analogous results were obtained in an in vitro 
splicing assay utilizing HeLa cell nuclear extract. 
E16 splicing efficiency in the wild type pre- 
mRNA was dramatically reduced by deletion of 
the hexamer element; insertion of intact UGCAUG 
elements, but not mutated hexamers, rescued E16 
splicing (data not shown). These results indicated 
that UGCAUG represents an intronic splicing 
enhancer for E16 splicing. 
Fox splicing factors promote El  6 inclusion in a 
UGCAUG-dependent manner. The results above are 
consistent with a model in which Fox-1 and Fox-2 
function as UGCAUG-dependent splicing factors 
that activate E16 splicing. This hypothesis was 
tested directly using a HeLa cell transfection 
strategy, asking whether Fox-1 or Fox-2 
expression plasmids could stimulate E 16 inclusion 
in 4.1 pre-mRNAs. Whereas the transfected wild 
type 4.1R construct alone exhibited only about 
35% inclusion (Figure 5A, 4. lWt), co-transfection 
with a full length Fox-1 or Fox-2 expression 
plasmid significantly increased E16 inclusion to 
80% or to 70%, respectively. Additional 
transfection experiments revealed that despite the 
difference in C-terminal sequences of Fox-2a and 
Fox-2P, no significant difference in their ability to 
stimulate E16 splicing was observed (data not 
shown) . 
To test whether this observed Fox-protein 
enhancer activity was dependent on the presence 
of UGCAUG, further transfection experiments were 
performed. Pre-mRNA constructs containing or 
lacking the UGCAUG elements were co-transfected 
with the Fox-1 or Fox-2 expression plasmids. In 
contrast to the wild type pre-mRNA transfection, 
neither protein stimulated E16 splicing in pre- 
mRNA substrates from which the hexamers were 
deleted (construct 4.1 Ahex). Replacement of wild 
type hexamers (construct 4. lAhexW) but not 
mutated hexamers (construct 4.1 Ahexmut) strongly 
restored the ability of Fox-1 and Fox-2 to 
stimulate E16 splicing. The low level of splicing 
stimulated by Fox-2 in construct 4. lAhexmut is not 
understood and may indicate that splicing 
regulation is more complex in vivo; however, the 
major enhancement of splicing by Fox-2 is clearly 
UGCAUG-de pe ndent . 
To confirm, that Fox-proteins are indeed 
expressed even in the constructs that show no E16 
splicing, immunoblot analysis was performed 
(Figure 5B). As expected, in those cells that 
contain the Fox expression plasmid, a stronger 
Fox-1 or Fox-2 signal could be detected (indicated 
by an arrow) in comparison to all other 
transfection samples. This observation is not due 
to a larger amount of protein sample loaded on the 
gel as demonstrated by the actin detection (Figure 
5B, lower panels). 
Together, these results suggest that both Fox 
proteins can rescue splicing in a UGCAUG- 
dependent manner. 
To further confirm the correlation of Fox- 
proteins and E16 splicing, the effect on splicing 
was investigated when the protein expression was 
decreased by RNA interference. Therefore HeLa 
cells were transfected with the 4.1R minigene 
construct and siRNA duplexes against the Fox-2 
gene. As shown in Figure 6, co-transfection with 
siRNA duplex 1 led to a substantial reduction of 
E16 splicing in comparison to the wildtype pre- 
mRNA. This result correlates with a decrease in 
Fox-2 expression, demonstrated by immunoblot 
(Figure 6, middle panel). SiRNA duplex 2 caused 
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a more dramatic effect: about 50% knockdown of 
Fox-2 protein was achieved leading to a nearly 
complete loss of E16 inclusion compared to the 
4.1R pre-mRNA. Taken together, these data 
indicate that Fox-proteins are splicing factors that 
enhance E16 splicing in HeLa cells. 
hFox-1 and mFox-2 bind specijcally to the 
UGCAUG elements in 4.1R intron 16. Several 
observations suggest that splicing activity of Fox-1 
and Fox-2 requires binding to UGCAUG elements 
in 4.1R intron 16: the SELEX identification of 
UGCAUG as the binding site for hFox-1; the 
identity of the RRM domain of Fox-1 and Fox-2; 
and the UGCAUG-dependence of both proteins’ 
enhancer activities. In order to directly 
demonstrate UGCAUG-dependent binding, we 
expressed recombinant Fox proteins by in vitro 
transcription and translation and tested their ability 
to bind wild type or mutated intron 16 sequences. 
Biotinylated RNAs representing the region 80-1 18 
nt downstream of E16 were employed in a 
pulldown assay to assess binding. Each RNA 
contained either two wild type UGCAUG elements 
or two mutated U G K U G  hexamers. As shown in 
Figure 7, wild type intron 16 sequence pulled 
down both hFox-1 and mFox-2 (lanes “hexwt”); in 
contrast, mutant intron 16 RNA bound much lower 
quantities of either protein when assayed in 
parallel under identical conditions (lanes “hexmUt”). 
The immunoblot using anti-hnRNP A1 serves as a 
control to demonstrate the integrity of the mutant 
oligonucleotide by virtue of its ability to bind 
hnRNP A1 similarly to the wild type RNA 
sequence. Notably, the mutant hexamer was 
defective both in binding to Fox- 1/Fox-2 proteins, 
as well as in its enhancer activity for E16 splicing. 
This correlation strongly suggests that binding is 
directly relevant to enhancer activity. 
Expression of Fox-2 in erythroidprogenitor cells. 
If Fox splicing factors play a role in activating the 
alternative splicing switch of E16 during erythroid 
differentiation, one would predict that Fox-2 
expression levels should increase relative to that of 
the silencing factor hnRNP A1 (23). This 
hypothesis was tested using the in vitro 
differentiation system for mouse erythroblasts 
isolated from the spleen of Friend virus-infected 
mice. As demonstrated earlier (23), E16 was 
excluded in RNA prepared from freshly isolated 
mouse erythroblasts, but included much more 
efficiently in RNA prepared from erythroblasts 
differentiated in the presence of erythropoietin 
(Figure 8, upper panel). Protein extracts prepared 
at time points before and after the splicing switch 
were then immunoblotted with antibodies to both 
Fox-2 and hnRNP Al .  Fox-2 was detected in the 
early erythroblasts, and levels changed little in 
mature cells after the splicing switch (Figure 8, 
middle panel). In contrast, hnRNP A1 expression 
was significantly reduced after the splicing switch 
(Figure 8, lower panel). These results reveal a 
substantial increase in the Fox-2:hnRNP A1 
expression ratio, consistent with a physiological 
role for Fox-2 in regulating alternative splicing in 
late erythroid differentiation. 
DISCUSSION 
In this paper we have demonstrated that the Fox 
family of pre-mRNA splicing regulatory proteins, 
acting through UGCAUG intronic enhancer 
element(s), stimulates inclusion of alternative E 16 
in protein 4.1R pre-mRNA. These results provide 
new insights into the tissue-specific control of E16 
splicing. 
According to our working model, E16 splicing 
is an ordered process that begins with activation of 
the weak 5’ splice site to facilitate removal of the 
downstream intron (21). Use of this 5’ splice site is 
inhibited directly or indirectly by binding of 
hnRNP A/B proteins to a well characterized 
silencer element in E16 (45), a putative second 
exonic site (our unpublished results), and 
potentially in the downstream intron as well 
(Figure 9). Counterbalancing silencer activity are 
multiple enhancer elements in the purine-rich 
region of E16 (23), in the downstream conserved 
region of the exon (46), and in the downstream 
intron (22). This suggests a multiple mode of 
regulation through dynamic antagonism (47) 
among opposing silencer and enhancer activities. 
Competition between Fox- 1/Fox-2 and hnRNP A 1 
may be one important determinant of E16 splicing 
efficiency. Indeed, down-regulation of hnRNP A1 
expression in late erythropoiesis relieves the 
splicing silencing activity to allow activation of 
E16 splicing (23). 
E16 is included not only in late stage 
erythroblasts, but also in muscle and in brain 
(9,10,13). Therefore, there may be more than one 
mechanism for cells to integrate input from 
distinct differentiation signals to make a splicing 
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decision to include E16. For example, while 
downregulation of hnRNP A1 is critical for E16 
activation in erythroid cells, increased expression 
of Fox proteins in muscle and/or brain might be 
sufficient to switch on E16 splicing, independent 
of changes in cellular hnRNP A1 levels. 
Experiments exploring splicing factors interactions 
during muscle, and neural differentiation will be 
required to fully elucidate the splicing regulatory 
networks responsible for E16 regulation in various 
cell types. The observation that Fox-2 is 
significantly expressed in mouse erythroblasts 
suggests that it is a likely physiological activator 
of splicing in differentiating erythroid cells. 
We propose that Fox-2 and its homologs play 
an important role in tissue-specific alternative 
splicing regulation in metazoan organisms, 
perhaps by functioning as part of a molecular 
switch acting at intronic UGCAUG enhancer 
elements to activate exon inclusion with the 
appropriate temporal and spatial specificity. This 
hypothesis is supported by the observations that 
UGCAUG is a critical regulatory element for proper 
tissue-specific splicing of calcitonidCGRP, 
fibronectin, myosin I1 heavy chain-B, and c-src 
pre-mRNAs (41-44,48); that UGCAUG is 
statistically highly over-represented in the 
proximal downstream intron of many brain- and 
muscle-specific exons (25,26,49); that 
recombinant Fox- 1 promotes muscle-specific 
splicing in a (U)GCAUG-dependent manner (24); 
and that Fox-2 enhances inclusion of an exon 
normally activated during erythroid differentiation 
(this paper). We speculate that the h g h  binding 
specificity of Fox proteins is advantageous for 
splicing switch mechanism(s) designed to activate 
a limited repertoire of splicing events in response 
to a specific signaling mechanism in a specific cell 
type. Increased cellular levels of Fox splicing 
activity could then facilitate splicing switches in 
selected target transcripts, analogous to the 
stimulation of 4.1R E16 splicing that occurs in 
Fox-transfected HeLa cells, without effecting large 
general changes in splicing of many pre-mRNAs. 
The reported upregulation of Fox-2/ RBM9 in 
androgen-stimulated spinal motor neurons (3 1) 
suggests that it would be interesting to examine 
these cells for potential Fox-2-mediated activation 
of brain-specific exons reported earlier to possess 
proximal intronic UGCAUG elements (25). 
Alternatively, decreased expression of antagonistic 
splicing inhibitor proteins could also activate 
splicing of Fox-responsive exons. 
Fox proteins have a long evolutionary history, 
with close homologs in the genomes of C. elegans 
and Drosophila in addition to the zebrafish protein 
reported earlier. Likewise, the UGCAUG binding 
sites for Fox splicing factors are conserved not 
only in the proximal intron sequences of 4.1R E16 
(Figure 3), but also adjacent to brain-specific 
exons from several vertebrate orders (25,26). It 
will be interesting to elucidate the full extent of 
Fox splicing factor function in the regulation of 
alternative splicing in various cell types in higher 
eukaryotes. Many questions remain to be 
addressed concerning the mechanism of action for 
this exciting new class of splicing regulators. One 
might speculate that Fox proteins function as 
adaptors to recruit spliceosomal machinery to a 
regulated exon (50), perhaps synergizing with the 
action of exonic SR proteins, or with other intronic 
activators (e.g., (5 1). Another vitally important 
issue relates to how Fox enhancer activity could be 
regulated in a tissue-specific manner, especially 
given the apparent expression of Fox proteins in 
multiple tissues. Do the same two (or a few) Fox 
genes mediate splicing switches in the appropriate 
temporal and spatial patterns during differentiation 
of various types of neural and muscle cells, as well 
as erythroid and potentially other cell types? These 
issues are likely to be as interesting as they are 
complex. Analogous to several other splicing 
factors, the Fox proteins exist as a mixture of 
alternatively spliced isoforms (27,32,33). Future 
studies will likely reveal that tissue-specific 
expression of splicing co-activator proteins, and/or 
tissue-specific expression of functionally distinct 
Fox protein spliceoforms, is an essential 
requirement for precise developmental regulation. 
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FIGURE LEGENDS 
Fig. 1. Binding specificity of human Fox-1 for the hexamer UGCAUG. Shown are the winner sequences 
identified in an in vitro selection experiment performed with recombinant hFox-1. The sequences are 
aligned with respect to the hexamer UGCAUG, shared by 45/47 selected sequences in this experiment 
(boxed). The remaining two winner sequences (Hl-51 and H1-58) possessed a very similar sequence, 
AGCAUG. Also boxed are the second UGCAUG elements found in four sequences. 
Fig. 2. Domain structure of Fox-1 and Fox-2. Shown are three Fox proteins used in this study, including 
one isoform of hFox-1 and two isoforms of mFox-2. RNA binding domain of each protein is indicated 
(solid black). Numbers represent the percent identity in amino acid sequence among the three proteins. 
mFox-2P possesses a distinct C-terminal domain (solid gray) due to alternative splicing. 
Fig. 3. Conserved hexamer elements flanking protein 4.1 exon 16. Upper panel shows a portion of the 
4.1R gene from exon 13 to exon 17, and illustrates the splicing switch that occurs during erythroid 
differentiation. 4.1R mRNA spliced in early progenitors skips E16, and the resulting protein has a low 
affinity spectrin-actin binding (SAB) domain. Late erythroblasts include E 16 efficiently and synthesize 
4.1R protein with a high affinity for binding to spectrin and actin. Exons 14 and 15 are skipped in 
erythroid cells but included in selected nonerythroid cells. Lower panel shows the presence of conserved 
UGCAUG elements (circles) in intron 16 of 4. lR, 4.1G and 4.1B genes of the indicated species. 
Fig. 4. UGCAUG is an intronic enhancer of 4.1R exon 16 splicing. Upper panel shows a model of the 4.1R 
minigene and 4.1R minigene mutants. RNA 4.lAhex lacks all three UGCAUG elements due to a 186 nt 
deletion, whereas RNA 4.1Ahexwt has four copies of the UGCAUG element reinserted, and RNA 
4. lAhexmut has four copies of a mutated element U G K U G  reinserted into the deletion construct. Lower 
panel shows the splicing phenotype of each pre-mRNA. 4.1R minigenes were transfected into HeLa cells 
and the resulting spliced mRNAs were analyzed by RT-PCR using primers selective for the transfected 
sequence. Analysis of PCR products by electrophoresis shows a larger product (including E16) in the 
upper band and a smaller product (excluding E16) in the lower band. 
Fig. 5. Fox-1 and Fox-2 are UGCAUG-dependent splicing enhancers for exon 16 splicing. A, UGCAUG- 
dependent Fox protein enhancer activity. Shown is the splicing efficiency of E16 in four pre-mRNA 
substrates that contain (4. lW and 4. lAhexwt) or lack (4.1 Ahex and 4. lAhexmut) UGCAUG splicing enhancer 
elements. For each construct, six transfections were performed: duplicate transfections without added 
enhancer; two with co-transfection of Fox-1, and two with co-transfection of Fox-2. Only constructs with 
UGCAUG enhancers exhibited strong stimulation of E16 splicing in response to co-transfected Fox 
proteins. Numbers below each lane indicate the percent inclusion of E16. B, Expression of Fox-1, Fox-2 
and actin verified by immunoblot analysis. The samples described in 5(A) were examined with regard to 
Fox-1 and Fox-2 protein expression. The transfected Fox-1 with -50 kDa and Fox-2 with -52 kDa are 
indicated by an arrow. Actin serves as indicator for the amount of protein on the gel. 
Fig. 6. SiRNA treatment confirms the correlation of Fox-2 and exon 16 splicing. HeLa cells were 
transfected with the 4.1R minigene alone or in combination with Fox-2 siRNA duplex 1 or duplex 2. The 
upper panel shows the splicing efficiency of E16. Number below each lane indicates the percent inclusion 
of E16. In the lower panel immunoblots depict the expression of Fox-2 and actin. 
Fig. 7. Binding of Fox-1 and Fox-2 to UGCAUG elements in intron 16. Pull-down experiment with in 
vitro-synthesized Fox- 1 (left), Fox-2 (middle) or hnRNP A1 (right) proteins using biotinylated wild type 
RNA containing two wild type UGCAUG elements or two mutated UGACUG hexamers. Proteins bound to 
the RNA probes immunoblotted with anti-Fox-1 (left) or anti-Fox-2 (middle) or anti-hnRNP A1 (right). 
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Fig. 8. Fox-2:hnRNP A1 ratio in mouse erythroid differentiation. Erythroblasts from mice treated with the 
anemia-inducing strain of Friend virus (FVA cells) were cultivated in vitro in the presence of 
erythropoietin. RT-PCR analysis of E16 splicing patterns in erythroblasts cultured for 24 and 45h (upper 
panel) and immunoblot analysis detecting Fox-2 (-48 kDa) and hnRNP A1 (-33 kDa) proteins before and 
after the splicing switch (lower panels). Actin serves as control for the amount of protein loaded on the 
gel. 
Fig. 9. Regulatory elements and splicing factors that control exon 16 alternative splicing. Splicing 
enhancer elements in E16 (ESE) and the downstream intron (ISE) are proposed to stimulate splicing at the 
5’ splice site. Further, each enhancer is proposed to be antagonized by adjacent or overlapping silencer 
elements, including a known hnRNP Al-binding silencer element in the exon (ESS) and a putative 
silencer in the intron (ISS). Antagonism between the exonic elements has been reported earlier (20). A 
second putative silencer element may be located in the 5’ region of the exon (unpublished results). Three 
UGCAUG repeats are located within 140 nt downstream of E16. 
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